Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company saw a slight decrease in revenue compared to the previous year, but net profit increased, indicating improved operational efficiency. The financials show a positive cash flow and an increase in total assets, suggesting a stable financial position. However, the figures have not been audited and may be subject to adjustments, prompting caution among investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a major player in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company holds a significant equity interest in Jiangzhong Pharmaceutical, which is listed on the Shanghai Stock Exchange.
Average Trading Volume: 16,744,630
Technical Sentiment Signal: Sell
Current Market Cap: HK$30.6B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.